Article
Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity Prediction
1 Oct 2022
Abstract excerpt
Neoantigens derived from somatic DNA alterations are ideal cancer-specific targets. In recent years, the combination therapy of PD-1/PD-L1 blockers and neoantigen vaccines has shown clinical efficacy in original PD-1/PD-L1 blocker non-responders. However, not all somatic DNA mutations result in immunogenicity among cancer cells and efficient tools to predict the immunogenicity of neoepitopes are still urgently...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
